ABCL (AbCellera Biologics) Total Stockholders Equity: $938.08 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABCL AbCellera Biologics Inc ABCL
60 GF Score
Price $6.16
GF Value $5.30
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is AbCellera Biologics Total Stockholders Equity?

AbCellera Biologics ABCL -0.16% 60 Total Stockholders Equity is $938.08 Mil as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 60/100 and a GF Value™ of $5.30 (Modestly Overvalued). The stock has 3 warning signs investors should review.

AbCellera Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $938.08 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AbCellera Biologics's Book Value per Share for the quarter that ended in Mar. 2026 was $3.09. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AbCellera Biologics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.15.

AbCellera Biologics  (NAS:ABCL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AbCellera Biologics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(938.083-0)/303.946
=3.09

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AbCellera Biologics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.869 + 134.309) / 938.083
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Total Stockholders Equity Related Terms

AbCellera Biologics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Total Stockholders Equity Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 1,025.73 1,233.28 1,152.32 1,056.08 966.90

AbCellera Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,022.98 1,007.08 964.04 966.90 938.08
ABCL
60GF Score
AbCellera Biologics Inc ABCL
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $938.08 Mil mean?
AbCellera Biologics (ABCL) has a Total Stockholders Equity of $938.08 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for AbCellera Biologics and its competitors.
Is AbCellera Biologics' Total Stockholders Equity too high?
AbCellera Biologics' current Total Stockholders Equity is $938.08 Mil. Overall, AbCellera Biologics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Total Stockholders Equity compare to AGIO and KOD?
AbCellera Biologics' Total Stockholders Equity of $938.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for AbCellera Biologics and its competitors. AbCellera Biologics's current Total Stockholders Equity is $938.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.30, compared to a current price of $6.16 — trading 16.2% above its estimated fair value. The current Total Stockholders Equity is $938.08 Mil. AbCellera Biologics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Total Stockholders Equity is $938.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $6.16 is trading 16.2% above its estimated GF Value™ of $5.30. GuruFocus considers AbCellera Biologics to be Modestly Overvalued.

Key valuation signals for ABCL:

  • Total Stockholders Equity: $938.08 Mil
  • GF Value™: $5.30 vs. price of $6.16 (16.2% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
60GF Score

Get the complete analysis for ABCL

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.16
Price
$5.30
GF Value